leadf
logo-loader
ASX:OCC

Orthocell Ltd

Receive alerts
Market:
ASX
Market Cap:
$97.68 m
Price
0.51 AUD
Change
6.25%
52 weeks high
0.66
52 weeks low
0.32

In brief

Orthocell Ltd (ASX:OCC) is focused on regenerating mobility for patients by developing innovative products for the repair of a variety of bone and soft tissue injuries.

Orthocell’s portfolio of products includes CelGro®, a collagen medical device that facilitates tissue repair and healing in a variety of orthopaedic, reconstructive, and surgical applications.

CelGro has received regulatory approval in the EU, Australia and the US for bone and soft tissue regeneration in dental procedures.

Snapshot

  • Orthocell explores new application for CelGro® platform in ACL reconstruction
  • Orthocell sets stage for commercialisation progress with CelGro®, Striate+ and Ortho-ATI® after busy June quarter
  • Orthocell looks ahead to results from OrthoATI shoulder tendon study in Q4

Insight Widest with the analysis, Proactive gives perspectives that others don't.

Orthocell sets stage for commercialisation progress with CelGro®, Striate+ and Ortho-ATI® after busy June quarter

The ASX-lister tabled data from a key CelGro® nerve regeneration trial and worked towards getting its Striate+ product to the US market over the June quarter, with data from a rotator cuff trial...

on 28/7/21